DCG-IV

DCG-IV
IUPAC ime
	(1R,2R)-3-[(1S)-1-amino-2-hidroksi-2-oksoetil]ciklopropan-1,2-dikarboksilna kiselina
Identifikatori
CAS broj	147782-19-2
ATC kod	none
PubChem	CID 5310979
Hemijski podaci
Formula	C7H9NO6
Molarna masa	203,149 g/mol
	SMILES [C@@H]1([C@@H](C1[C@@H](C(=O)O)N)C(=O)O)C(=O)O; ;

DCG-IV je lek koji se koristi u naučnim istraživanjima. On deluje kao agonist za grupu II metabotropnih glutamatnih receptora (mGluR₂_/₃).^[1] On ima potentne neuroprotektivne i antikonvulsantne efekte u životinjskim studijama.^[2]^[3]^[4]^[5] On isto tako pokazuje antiparkinsonove efekte,^[6]^[7] mada je poznato da usporava formiranje memorija.^[8]^[9]

Reference

^ Ishida M, Saitoh T, Shimamoto K, Ohfune Y, Shinozaki H (1993). „A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the newborn rat isolated spinal cord”. British Journal of Pharmacology. 109 (4): 1169—77. PMC 2175774 . PMID 8401927.
^ Bruno V, Copani A, Battaglia G, Raffaele R, Shinozaki H, Nicoletti F (1994). „Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death”. European Journal of Pharmacology. 256 (1): 109—12. PMID 7517889. doi:10.1016/0014-2999(94)90624-6.
^ Yoshioka H, Sugita M, Kinouchi H (2009). „Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia”. Neuroscience Letters. 461 (3): 266—70. PMID 19549561. doi:10.1016/j.neulet.2009.06.056.
^ Attwell PJ, Singh Kent N, Jane DE, Croucher MJ, Bradford HF (1998). „Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV)”. Brain Research. 805 (1-2): 138—43. PMID 9733953. doi:10.1016/S0006-8993(98)00698-2.
^ Fei Z, Zhang X, Bai HM, Jiang XF, Wang XL (2006). „Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury”. Journal of Clinical Neuroscience. 13 (10): 1023—7. PMID 17113985. doi:10.1016/j.jocn.2005.11.042.
^ Dawson L, Chadha A, Megalou M, Duty S (2000). „The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat”. British Journal of Pharmacology. 129 (3): 541—6. PMC 1571875 . PMID 10711353. doi:10.1038/sj.bjp.0703105.
^ Venero JL, Santiago M, Tomás-Camardiel M, Matarredona ER, Cano J, Machado A (2002). „DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury”. Neuroscience. 113 (4): 857—69. PMID 12182892. doi:10.1016/S0306-4522(02)00232-4.
^ Huang LQ, Rowan MJ, Anwyl R (1997). „mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD induction, in the dentate gyrus in vitro”. Neuroreport. 8 (3): 687—93. PMID 9106748. doi:10.1097/00001756-199702100-00022.
^ Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (2004). „Inhibitory effects of group II mGluR-related drugs on memory performance in mice”. Physiology & Behavior. 80 (5): 747—58. PMID 14984810. doi:10.1016/j.physbeh.2003.12.010.

Spoljašnje veze

[pmid8401927-1] Ishida M, Saitoh T, Shimamoto K, Ohfune Y, Shinozaki H (1993). „A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the newborn rat isolated spinal cord”. British Journal of Pharmacology. 109 (4): 1169—77. PMC 2175774 . PMID 8401927.

[pmid7517889-2] Bruno V, Copani A, Battaglia G, Raffaele R, Shinozaki H, Nicoletti F (1994). „Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death”. European Journal of Pharmacology. 256 (1): 109—12. PMID 7517889. doi:10.1016/0014-2999(94)90624-6.

[pmid19549561-3] Yoshioka H, Sugita M, Kinouchi H (2009). „Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia”. Neuroscience Letters. 461 (3): 266—70. PMID 19549561. doi:10.1016/j.neulet.2009.06.056.

[pmid9733953-4] Attwell PJ, Singh Kent N, Jane DE, Croucher MJ, Bradford HF (1998). „Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV)”. Brain Research. 805 (1-2): 138—43. PMID 9733953. doi:10.1016/S0006-8993(98)00698-2.

[pmid17113985-5] Fei Z, Zhang X, Bai HM, Jiang XF, Wang XL (2006). „Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury”. Journal of Clinical Neuroscience. 13 (10): 1023—7. PMID 17113985. doi:10.1016/j.jocn.2005.11.042.

[pmid10711353-6] Dawson L, Chadha A, Megalou M, Duty S (2000). „The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat”. British Journal of Pharmacology. 129 (3): 541—6. PMC 1571875 . PMID 10711353. doi:10.1038/sj.bjp.0703105.

[pmid12182892-7] Venero JL, Santiago M, Tomás-Camardiel M, Matarredona ER, Cano J, Machado A (2002). „DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury”. Neuroscience. 113 (4): 857—69. PMID 12182892. doi:10.1016/S0306-4522(02)00232-4.

[pmid9106748-8] Huang LQ, Rowan MJ, Anwyl R (1997). „mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD induction, in the dentate gyrus in vitro”. Neuroreport. 8 (3): 687—93. PMID 9106748. doi:10.1097/00001756-199702100-00022.

[pmid14984810-9] Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (2004). „Inhibitory effects of group II mGluR-related drugs on memory performance in mice”. Physiology & Behavior. 80 (5): 747—58. PMID 14984810. doi:10.1016/j.physbeh.2003.12.010.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]